<DOC>
	<DOCNO>NCT02907983</DOCNO>
	<brief_summary>Hot flash night sweat ( i.e. , vasomotor symptom , VMS ) affect 80 % woman menopausal transition ( MT ) . VMS associate decrease quality life , increase depressive anxiety symptom , memory complaint , sleep disturbance , reduce work productivity . Hormone therapy ( HT ) highly effective reduce VMS , use HT decline 75 % 80 % U.S. Women 's Health Initiative ( WHI ) raise safety concern HT . In 2013 , Food Drug Administration ( FDA ) approve paroxetine , selective serotonin reuptake inhibitor ( SSRI ; 7.5 mg ) , first non-hormonal treatment VMS . SSRIs important treatment option many woman , use treat VMS limit low effectiveness compare HT , side effect , relapse symptom follow treatment discontinuation . Identifying safe effective non-hormonal treatment VMS remain priority woman 's health research . Stellate ganglion blockade ( SGB ) , use decade pain management , potential new approach VMS treatment . Located cervical spine region , stellate ganglion part sympathetic nervous system . Although SGB commonly perform treat neuropathic pain , hyperhidrosis vascular insufficiency , anatomic study reveal connection ganglion thermoregulatory region brain , specifically insular cortex . In clinical trial , aim ass whether stellate ganglion block ( SGB ) bupivacaine , local anesthetic , effective safe non-hormonal intervention woman seek relief vasomotor symptom ( VMS ) , identify physiologic mechanism underlie SGB effect . Outcomes include frequency intensity hot flash , objectively-measured VMS , mood , quality life , sleep , memory performance 220 postmenopausal woman 28 moderate severe hot flash per week measure self-report six month . They reassess 3 6 month follow SGB sham intervention objective hot flash quality life measure . Mechanistic outcome ( neuroimaging ) obtain baseline 3 month follow intervention . Ambulatory monitor sympathetic nervous system function ( SKNA ) perform baseline procedure , procedure 1 hour follow procedure . This repeat 2 four week follow SGB sham procedure 1 hour recording .</brief_summary>
	<brief_title>SGB Post-Menopausal Women</brief_title>
	<detailed_description>Scope : Post-menopausal woman moderate severe VMS enrol participant study . Hypotheses : We predict compare sham intervention , SGB reduce frequency VMS , improve mood anxiety , increase quality life , improve memory , normalize brain activity thermoregulatory brain area reduce efferent sympathetic nerve activity effect sleep cognitive function . By provide definitive understanding effectiveness SGB , possible secondary benefit , mechanisms action , finding fill critical gap treatment option available woman . Specific Goals Objectives : Aim 1 : To determine effect SGB reduce menopausal VMS . Hypothesis 1 : The frequency intensity VMS low woman randomize active SGB compare sham control . Aim 2 : To evaluate effect SGB objective VMS , mood , memory , sleep quality . Hypothesis 2a : The frequency objectively measure VMS low woman randomize active SGB compare sham control . Hypothesis 2b : Depressive symptom memory , sleep quality , improve woman randomize active SGB compare sham control . Hypothesis 2c : The magnitude improvement memory relate magnitude reduction VMS , even control sleep . Aim 3 : To probe mechanism SGB improve VMS . Hypothesis 3a : In nested substudy , neuroimaging assessment reveal compare sham control , active SGB associate ) decrease functional connectivity default mode network rest state , particularly network support insula hippocampus ; b ) reduce activation hippocampus , dorsolateral prefrontal cortex , anterior cingulate verbal memory task ; c ) reduce activation amygdala emotion processing task . Hypothesis 3b : Compared sham control , SGB immediately diminish ipsilateral stellate ganglion nerve activity sympathetic tone .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<criteria>1. age 40 70 year ; cognition testing , upper age limit 62 2 . 28 report moderatetovery severe hot flash per week 3. minimum two week VMS diary record prior SGB 4. willingness undergo fluoroscopyguided SGB sham treatment . 1. condition preclude SGB sham intervention ( e.g. , anatomic abnormality anterior neck cervical spine ; goiter , cardiac/pulmonary compromise ; acute illness/infection ; coagulopathy bleeding disorder ; allergic reactions/contraindications local anesthetic contrast dye , uncontrolled hypertension define systolic BP &gt; 190 mm Hg diastolic BP &gt; 100 mm Hg 2 . FSH &lt; 50 ml U/ml , 3. use treatment two prior month affect VMS frequency severity , include oral transdermal hormone therapy , botanical ( e.g. , soy , red clover , black cohosh , etc . ) , oral contraceptive , serotonin selective reuptake inhibitor ( SSRI ) , serotonin norepinephrine reuptake inhibitor ( SNRI ) , gabapentin , pregabalin , clonidine , selective estrogen receptor modulators , aromatase inhibitor , tissue selective estrogen complex ; 4 . For cognition testing : condition disorder affect performance cognitive test ( e.g. , dementia/mild cognitive impairment , MiniMental State Exam ( MMSE ) great equal 27 ) ; stroke ; traumatic brain injury ; alcohol/substance use ; inability write , speak , read English , English second language , participation study involve test cognitive ability 5. condition affect depressive symptom ( e.g. , current diagnosis major depression , bipolar disorder , Axis I Psychiatric disorder ) ; Beck Depression Inventory ( BDI ) &gt; 30 6 . Exclusion criterion neuroimaging study : implantable pulse generator pacemaker , defibrillator device spinal cord stimulators deep brain stimulator , ferrouscontaining metal within body ( e.g. , brace , aneurysm clip , shrapnel/retained particle ) inability tolerate small , enclosed space without anxiety ( e.g . claustrophobia ) , weight &gt; 300 lb . unless height sufficiently high [ e.g. , + 5'11 '' ] waist shoulder circumference prevent fitting scanner ; 7 . Exclusion criterion SKNA study allergic adhesive electrode</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Menopause</keyword>
	<keyword>Post-menopausal</keyword>
</DOC>